Theramex is a company steeped in history, with a strong commitment to Women’s Health dating back several decades.
The brand Theramex was established
The company began to grow with the launch of a treatment for postmenopausal vaginal atrophy
This growth continued with the introduction of an in-house development of progestin, indicated for pre-menopausal women with menstrual disorders and, in combination with an estrogen, for menopause
Merck acquired Theramex and launched a menopause patch, providing a great platform to expand women’s healthcare throughout Europe and international markets
Partnered with Organon to co‑develop and co‑market a monophasic estradiol pill for the contraception market
Teva Pharmaceuticals acquired Theramex and the company rebranded as Teva Women’s Health. The branded generics portfolio was expanded with the addition of new contraceptive and osteoporosis products
A fertility franchise was developed with the launch of follitropin alfa, and the addition of an oral bisphosphonate expanded the osteoporosis franchise
The Teva Women’s Health division was sold by Teva Pharmaceuticals to CVC Capital Partners, to create
an international pharmaceutical company dedicated to Women’s Health.
The new Theramex was born
Read more about the acquisition here